Director First Moscow State Medical University Russia
Sergey Suchkov was born in the City of Astrakhan, Russia. In 1980, graduated from Astrakhan State Medical University and was awarded with MD. In 1985, maintained his PhD at the I.M. Sechenov Moscow Medical Academy and Inst of Med Enzymology. In 2001, and then his Doctor Degree at the Nat Inst of Immunology in Russia.
From 1989 through 1995, was being a Head of the Lab of Clin Immunology, Helmholtz Eye Research Inst in Moscow. From 1995 through 2004 - a Chair of the Dept for Clin Immunology, Moscow Clin Research Institute (MONIKI). In 1993-1996, was a Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK.
At present, Dr Sergey Suchkov, MD, PhD, is:
â—Professor, Director, Center for Personalized Medicine, Sechenov University and Dept of Clinical Immunology, A.I.Evdokimov Moscow State Medical and Dental University;
â—Professor, Chair, Dept for Translational Medicine, Moscow Engineering Physical Institute (MEPhI), Russia
â—Secretary-General, United Cultural Convention (UCC), Cambridge, UK.
Dr Suchkov is a member of the:
â— New York Academy of Sciences, USA
â— American Chemical Society (ACS), USA;
â— American Heart Association (AHA), USA;
â—European Association for Medical Education (AMEE), Dundee, UK;
â—EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU;
â—ARVO (American Association for Research in Vision and Ophthalmology);
â— ISER (International Society for Eye Research);
â— Personalized Medicine Coalition (PMC), Washington, DC, USA
Dr Suchkov is a member of the Editorial Boards of “Open Journal of Immunology”, EPMA J., American J. of Cardiovascular Research and “Personalized Medicine Universe”
A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM). To achieve the implementation of PM concept, it is necessary to create a fundamentally new strategy based upon the subclinical recognition of biopredictors of hidden abnormalities long before the disease clinically manifests itself.
Each decision-maker values the impact of their decision to use PPM on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the patients resulting in improved patient outcomes, reduced adverse events, and more cost-effective use of health care resources. A lack of medical guidelines has been identified by the majority of responders as the predominant barrier for adoption, indicating a need for the development of best practices and guidelines to support the implementation of PPM!
Implementation of PPM requires a lot before the current model “physician-patient” could be gradually displaced by a new model “medical advisor-healthy person-at-risk”. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM to elicit the content of the new branch.